• Beans: powerful supporters in colorectal cancer aftercare

    The intestinal microbiome is essential in many body processes. Could prebiotic food intake benefit intestinal flora in intestinal polyps or colorectal carcinoma?

  • Promising results for novel CAR T-cell therapy in MM in phase 1 trial

    Anitocabtagene autoleucel (anito-cel) yielded excellent efficacy results in heavily pre-treated participants with relapsed or refractory multiple myeloma.

  • Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

    Isatuximab with bortezomib, lenalidomide + dexamethasone yielded better outcomes than VRd alone for first-line treatment of transplant-ineligible cases.

  • FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

    Treatment led to high measurable residual disease-negativity rates in European LeukaemiaNet subgroups for newly-diagnosed acute myeloid leukaemia.

  • Can golcadomide plus R-CHOP become the first-line standard of care in DLBCL?

    The combination delivered a high rate of durable complete metabolic responses regardless of cell of origin in aggressive B-cell lymphoma patients.

  • ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

    Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.

  • AI can diagnose CNS tumours during surgery

    An AI algorithm called "Sturgeon" can classify CNS tumours fast and accurately during surgery. This enables resection strategies adapted to tumour types.

  • DREAMM 8: belantamab mafodotin offers hope for patients with RR MM

    Belantamab mafodotin plus pomalidomide and dexamethasone PVd for progression-free survival in participants with relapsed or refractory multiple myeloma.

  • High survival rates following atezolizumab consolidation therapy in DLBCL

    High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.

  • APOLLO: ATRA plus ATO meets expectations in high-risk APL

    All-Trans Retinoic Acid plus Arsenic Trioxide was superior to ATRA-chemotherapy in event-free survival high-risk acute promyelocytic leukaemia.

  • The future of MASLD treatments

    Future hepatologists could have numerous drugs for MASLD control and treatment. Promising results from recent trials were presented at EASL 2024.

  • Integrated and personalized approach in the treatment of hepatocarcinoma

    During EASL 2024, the rise of AI in radiology and liver pathology; and of multisystem / multiscale integration in HCC patient care was discussed.

  • Artificial Intelligence in Hepatology: real promise or hype?

    AI is revolutionizing many fields, including hepatology. During EASL 2024, its clinical application was discussed, with a focus on personalized patient management.

  • Management of MASLD in 2030

    Which diagnostic and treatment pathways for MASLD patients will exist in 2030? Dr. Ian Rowe discusses patient management scenarios in the near future.

  • Differences in viral hepatitis management in children and adults

    A symposium addressed chronic viral hepatitis management in children, and whether all children with chronic viral hepatitis should be treated.

  • Interview: An overview of liver diseases

    Liver diseases expert Prof. Umberto Vespasiani-Gentilucci addresses important innovations in disease management with a focus on PBC and ‘real world’ data use.

  • Interview with Lea Münch: A look into psychiatry during the Nazi era

    Physician and medical historian Dr Lea Münch looked into psychiatric patients' treatment during the Nazi occupation of Alsace, from the patients' point of view.

  • Leukaemia Biology Debate: AML Focus

    AML reveals a complex interplay between malignant cells and their environment where disease progression and treatment response is orchestrated.

  • Allo-HSCT in Intermediate-Risk AML: Is It Needed?

    The journey to unravelling the complexities of AML treatment, especially in intermediate-risk patients, evolves as novel diagnositcs and therapies are embraced.

  • AML Classifications: WHO vs ICC 2022 Update

    Besides WHO's classification, ICC's system for AML diagnosis and treatment is also available since 2022. How do they differ and which should be followed?

  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |